Lucentis
Novartis’ Lucentis recommended for wider EU licence
October 25, 2010Sales and Marketing CHMP, Genentech, Lucentis, Novartis, diabetic macular edema, ranibizumab
Novartis’ Lucentis has been recommended for approval in Europe to treat people suffering from vison loss due to diabetes. The …
Lucentis boosted by diabetic vision study
May 24, 2010Research and Development, Sales and Marketing AMD, DME, Lucentis, Novartis
A phase III trial of Novartis’ ranibizumab has shown it to be superior at promoting vision gain in patients with …
NICE bends to pressure over Lucentis
December 14, 2007Sales and Marketing AMD, Lucentis, NICE
NICE is set to change its guidance for blindness treatment Lucentis following a barrage of complaints over its failure to …
NICE to re-think blindness drugs decision
August 9, 2007Sales and Marketing AMD, Lucentis, Macugen, NICE
NICE will delay issuing final guidance on two blindness drugs after an unprecedented patient outcry over its decision to block …
NICE set to block blindness drugs
June 15, 2007Sales and Marketing AMD, Lucentis, Macugen, NICE
Most patients in England and Wales will be denied access to drugs for the leading cause of sight loss if …
Lucentis approved in Europe
January 26, 2007Sales and Marketing Lucentis, Novartis
European regulators have approved Novartis’ Lucentis, a new treatment for neovascular age-related macular degeneration, known as wet AMD.The company says …
New blindness treatment moves closer to market
November 28, 2006Sales and Marketing AMD, Lucentis, Novartis
Patients suffering from the leading cause of blindness could soon benefit from a new treatment after it gained preliminary approval …
New Novartis blindness treatment filed in Europe
March 2, 2006Sales and Marketing AMD, Lucentis, Novartis
Lucentis, a new treatment for neovascular age-related macular degeneration or ‘wet AMD’ has been submitted by Novartis to the European …
